IL240014A0 - Treatment of multiple sclerosis using laquinimod - Google Patents

Treatment of multiple sclerosis using laquinimod

Info

Publication number
IL240014A0
IL240014A0 IL240014A IL24001415A IL240014A0 IL 240014 A0 IL240014 A0 IL 240014A0 IL 240014 A IL240014 A IL 240014A IL 24001415 A IL24001415 A IL 24001415A IL 240014 A0 IL240014 A0 IL 240014A0
Authority
IL
Israel
Prior art keywords
laquinimod
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
IL240014A
Other languages
English (en)
Hebrew (he)
Original Assignee
Teva Pharma
Hayardeny Liat
Tarcic Nora
Bar Zohar Dan
Gilgun Sherki Yossi
Gorfine Tali
Knappertz Volker
Sorani Ella
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL240014(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Hayardeny Liat, Tarcic Nora, Bar Zohar Dan, Gilgun Sherki Yossi, Gorfine Tali, Knappertz Volker, Sorani Ella filed Critical Teva Pharma
Publication of IL240014A0 publication Critical patent/IL240014A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL240014A 2013-02-15 2015-07-19 Treatment of multiple sclerosis using laquinimod IL240014A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
IL240014A0 true IL240014A0 (en) 2015-09-24

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240014A IL240014A0 (en) 2013-02-15 2015-07-19 Treatment of multiple sclerosis using laquinimod

Country Status (18)

Country Link
US (2) US20140235670A1 (OSRAM)
EP (1) EP2956137A4 (OSRAM)
JP (1) JP2016510343A (OSRAM)
KR (1) KR20150119227A (OSRAM)
CN (1) CN105163737A (OSRAM)
AU (1) AU2014216199A1 (OSRAM)
BR (1) BR112015019564A2 (OSRAM)
CA (1) CA2900503A1 (OSRAM)
CL (1) CL2015002181A1 (OSRAM)
EA (1) EA201591507A1 (OSRAM)
HK (2) HK1218251A1 (OSRAM)
IL (1) IL240014A0 (OSRAM)
MX (1) MX2015010296A (OSRAM)
PE (1) PE20151526A1 (OSRAM)
SG (1) SG11201505818WA (OSRAM)
TW (1) TW201442709A (OSRAM)
UY (1) UY35328A (OSRAM)
WO (1) WO2014127139A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
US10537566B2 (en) 2014-10-16 2020-01-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
WO2018178973A1 (en) * 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2009009529A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP2012512165A (ja) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2014521659A (ja) * 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
AU2015253330A1 (en) * 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

Also Published As

Publication number Publication date
HK1218251A1 (zh) 2017-02-10
EA201591507A1 (ru) 2015-12-30
TW201442709A (zh) 2014-11-16
CN105163737A (zh) 2015-12-16
PE20151526A1 (es) 2015-11-20
MX2015010296A (es) 2016-05-05
WO2014127139A1 (en) 2014-08-21
UY35328A (es) 2014-09-30
CA2900503A1 (en) 2014-08-21
US20180064702A1 (en) 2018-03-08
JP2016510343A (ja) 2016-04-07
BR112015019564A2 (pt) 2017-07-18
AU2014216199A1 (en) 2015-09-03
US20140235670A1 (en) 2014-08-21
EP2956137A1 (en) 2015-12-23
KR20150119227A (ko) 2015-10-23
HK1218254A1 (zh) 2017-02-10
CL2015002181A1 (es) 2016-06-03
SG11201505818WA (en) 2015-08-28
EP2956137A4 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
IL245408B (en) Converted benzamides for the treatment of arthropods
IL241101A0 (en) Medicinal uses of empagliflozin
SG11201507121RA (en) Treatment of cataplexy
IL241102A0 (en) Medicinal uses of empagliflozin
LT2981271T (lt) Empagliflozino terapinis panaudojimas
IL240014A0 (en) Treatment of multiple sclerosis using laquinimod
IL245373A0 (en) Treatment of glaucoma by laquinimod
IL241096B (en) Treatment methods
IL243486A0 (en) Treatment of multiple sclerosis using a combination of laquinimod and flupirtine
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
ZA201601626B (en) Treatment of gases
GB2525530B (en) Treatment of hard surfaces
IL246078A0 (en) Treatment of multiple sclerosis by a combination of laquinimod and triflunomide
HK1225291A1 (en) Laquinimod combination therapy for treatment of multiple sclerosis
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201306411D0 (en) Treatment of inflammatory conditions
AU2013901359A0 (en) Methods of Treatment